Equibles does not estimate personal net worth.
Get an email with a short summary when Dyadic International Inc publishes a filing, an earnings call transcript or a press release.
Get DYAI alertsJoseph Hazelton is recorded as COO at Dyadic International Inc (DYAI). The newest filing on record that lists Joseph Hazelton as COO at Dyadic International Inc (DYAI) is dated May 12, 2026. Dyadic International Inc reported in an 8-K filed June 2, 2025 that Joseph Hazelton was appointed President, effective May 29, 2025. Dyadic International Inc reported in an 8-K filed March 28, 2024 that Joseph Hazelton was appointed Chief Operating Officer, effective March 26, 2024. The proxy statement of Dyadic International Inc reports total compensation of $483,337 for Joseph Hazelton in fiscal 2025, including a base salary of $307,417. Disclosed compensation is on record for 2 fiscal years. Joseph Hazelton has spoken on 7 earnings calls across 1 company, most recently for Dyadic International Inc on November 12, 2025. Dyadic International Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyadic International Inc includes Mark Emalfarb (CEO and Board Member), Ping Rawson (CFO) and Patrick Lucy (Board Member).
“On May 29, 2025, the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) appointed Joseph Hazelton as President of the Company.”
“Also on March 26, 2024, the Board appointed Joseph Hazelton, its current Chief Business Officer, to the position of Chief Operating Officer, effective immediately.”
“The third quarter was another pivotal quarter for Dyadic International, Inc. as we continued our transformation from a platform-centric R&D organization into a commercially focused biotechnology company with a growing portfolio of high-value products.”
“Since I first joined the company in 2022, we've moved from being a platform-focused organization with deep science but limited commercial traction to one with a clear execution-driven strategy.”
“Our collaborations in alternative proteins and biopharmaceuticals demonstrate the impressive versatility and scalability of our platforms, emphasizing Dyadic's capability to deliver consistent, high-quality results across various applications.”
“In the second quarter, our business development efforts in the alternative protein sector are continuing to bear fruit, showcasing the potential of our microbial platforms.”
“Dyadic remains truly excited about the uses of its microbial platforms in the alternative protein sector. We believe this sector offers significant promise in terms of high-value markets and near-term revenue.”
Start not stated–present
Last confirmed May 12, 2026
Proxy statement
Start not stated–2023-04-27
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
COO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Dyadic International Inc (DYAI) | President and Chief Operating Officer | $307,417 | $483,337 |
| 2024 | Dyadic International Inc (DYAI) | President and Chief Operating Officer | $272,985 | $478,212 |
